Literature DB >> 28000105

Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis.

Kirtesh R Patel1, Stuart H Burri2, Danielle Boselli3, James T Symanowski3, Anthony L Asher4, Ashley Sumrall5, Robert W Fraser2, Robert H Press6, Jim Zhong6, Richard J Cassidy6, Jeffrey J Olson7, Walter J Curran6, Hui-Kuo G Shu6, Ian R Crocker6, Roshan S Prabhu2.   

Abstract

Pre-operative stereotactic radiosurgery (pre-SRS) has been shown as a viable treatment option for resectable brain metastases (BM). The aim of this study is to compare oncologic outcomes and toxicities for pre-SRS and post-operative WBRT (post-WBRT) for resectable BM. We reviewed records of consecutive patients who underwent resection of BM and either pre-SRS or post-WBRT between 2005 and 2013 at two institutions. Overall survival (OS) was calculated using the Kaplan-Meier method. Cumulative incidence was used for intracranial outcomes. Multivariate analysis (MVA) was performed using the Cox and Fine and Gray models, respectively. Overall, 102 patients underwent surgical resection of BM; 66 patients with 71 lesions received pre-SRS while 36 patients with 42 cavities received post-WBRT. Baseline characteristics were similar except for the pre-SRS cohort having more single lesions (65.2% vs. 38.9%, p = 0.001) and smaller median lesion volume (8.3 cc vs. 15.3 cc, p = 0.006). 1-year OS was similar between cohorts (58% vs. 56%, respectively) (p = 0.43). Intracranial outcomes were also similar (2-year outcomes, pre-SRS vs. post-WBRT): local recurrence: 24.5% vs. 25% (p = 0.81), distant brain failure (DBF): 53.2% vs. 45% (p = 0.66), and leptomeningeal disease (LMD) recurrence: 3.5% vs. 9.0% (p = 0.66). On MVA, radiation cohort was not independently associated with OS or any intracranial outcome. Crude rates of symptomatic radiation necrosis were 5.6 and 0%, respectively. OS and intracranial outcomes were similar for patients treated with pre-SRS or post-WBRT for resected BM. Pre-SRS is a viable alternative to post-WBRT for resected BM. Further confirmatory studies with neuro-cognitive outcomes comparing these two treatment paradigms are needed.

Entities:  

Keywords:  Brain metastases; Post-operative; Pre-operative; Resection; Stereotactic radiosurgery; Whole brain radiation therapy

Mesh:

Year:  2016        PMID: 28000105     DOI: 10.1007/s11060-016-2334-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

3.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

4.  Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone.

Authors:  Kirtesh R Patel; Roshan S Prabhu; Shravan Kandula; Daniel E Oliver; Sungjin Kim; Constantinos Hadjipanayis; Jeffery J Olson; Nelson Oyesiku; Walter J Curran; Mohammad K Khan; Hui-Kuo Shu; Ian Crocker
Journal:  J Neurooncol       Date:  2014-09-05       Impact factor: 4.130

5.  Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.

Authors:  Eric Ojerholm; John Y K Lee; Jayesh P Thawani; Denise Miller; Donald M O'Rourke; Jay F Dorsey; Geoffrey A Geiger; Suneel Nagda; James D Kolker; Robert A Lustig; Michelle Alonso-Basanta
Journal:  J Neurosurg       Date:  2014-12       Impact factor: 5.115

6.  Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.

Authors:  Matthew D Johnson; Vladimir Avkshtol; Andrew M Baschnagel; Kurt Meyer; Hong Ye; Inga S Grills; Peter Y Chen; Ann Maitz; Rick E Olson; Daniel R Pieper; Daniel J Krauss
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-19       Impact factor: 7.038

7.  Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery.

Authors:  Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

8.  BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.

Authors:  Kirtesh R Patel; Mudit Chowdhary; Jeffrey M Switchenko; Ragini Kudchadkar; David H Lawson; Richard J Cassidy; Roshan S Prabhu; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-08       Impact factor: 3.599

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.

Authors:  Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  J Neurooncol       Date:  2014-07-22       Impact factor: 4.130

View more
  18 in total

Review 1.  Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer.

Authors:  Thomas M Churilla; Stephanie E Weiss
Journal:  Curr Oncol Rep       Date:  2018-05-07       Impact factor: 5.075

2.  Tumor types, breast tumor subtypes and extension of systemic disease may influence outcome in cancer patients with brain metastases.

Authors:  Kadri Altundag
Journal:  J Neurooncol       Date:  2017-03-02       Impact factor: 4.130

3.  Postoperative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities.

Authors:  Jim Zhong; Matthew J Ferris; Jeffrey Switchenko; Robert H Press; Zachary Buchwald; Jeffrey J Olson; Bree R Eaton; Walter J Curran; Hui-Kuo G Shu; Ian R Crocker; Kirtesh R Patel
Journal:  Pract Radiat Oncol       Date:  2017-04-26

4.  Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Thomas M Churilla; Imran H Chowdhury; Elizabeth Handorf; Laurence Collette; Sandra Collette; Yanqun Dong; Brian M Alexander; Martin Kocher; Riccardo Soffietti; Elizabeth B Claus; Stephanie E Weiss
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

Review 5.  Neoadjuvant Stereotactic Radiosurgery: a Further Evolution in the Management of Brain Metastases.

Authors:  Cristian Udovicich; Claire Phillips; David L Kok; Damien Tange; Nikki M Plumridge; Roshan S Prabhu; Neda Haghighi
Journal:  Curr Oncol Rep       Date:  2019-07-04       Impact factor: 5.075

6.  Stereotactic Radiosurgery to Prevent Local Recurrence of Brain Metastasis After Surgery: Neoadjuvant Versus Adjuvant.

Authors:  Ian E McCutcheon
Journal:  Acta Neurochir Suppl       Date:  2021

Review 7.  Current approaches to the management of brain metastases.

Authors:  John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang
Journal:  Nat Rev Clin Oncol       Date:  2020-02-20       Impact factor: 66.675

8.  Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control.

Authors:  Evan D Bander; Melissa Yuan; Anne S Reiner; Katherine S Panageas; Åse M Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss
Journal:  Neurooncol Pract       Date:  2021-01-21

9.  Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience.

Authors:  Joseph A Carnevale; Brandon S Imber; Graham M Winston; Jacob L Goldberg; Ase Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss
Journal:  J Neurosurg       Date:  2021-09-10       Impact factor: 5.408

Review 10.  Mechanisms and Therapy for Cancer Metastasis to the Brain.

Authors:  Federica Franchino; Roberta Rudà; Riccardo Soffietti
Journal:  Front Oncol       Date:  2018-05-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.